241 related articles for article (PubMed ID: 28385602)
1. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
Wang C; Lv H; Yang W; Li T; Fang T; Lv G; Han Q; Dong L; Jiang T; Jiang B; Yang G; Wang H
Cancer Lett; 2017 Jul; 398():1-11. PubMed ID: 28385602
[TBL] [Abstract][Full Text] [Related]
2. Hormetic dose response to
Cho S; Chae JS; Shin H; Shin Y; Song H; Kim Y; Yoo BC; Roh K; Cho S; Kil EJ; Byun HS; Cho SH; Park S; Lee S; Yeom CH
Sci Rep; 2018 Jul; 8(1):11372. PubMed ID: 30054560
[No Abstract] [Full Text] [Related]
3. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment.
Hong SW; Lee SH; Moon JH; Hwang JJ; Kim DE; Ko E; Kim HS; Cho IJ; Kang JS; Kim DJ; Kim JE; Shin JS; Jung DJ; Jeong YJ; Cho BJ; Kim TW; Lee JS; Kang JS; Hwang YI; Noh DY; Jin DH; Lee WJ
Oncogene; 2013 Mar; 32(12):1508-17. PubMed ID: 22665050
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.
Zhao X; Zhang C; Zhou H; Xiao B; Cheng Y; Wang J; Yao F; Duan C; Chen R; Liu Y; Feng C; Li H; Li J; Dai R
Oncotarget; 2016 Dec; 7(51):85492-85501. PubMed ID: 27863431
[TBL] [Abstract][Full Text] [Related]
5. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
Jung SA; Lee DH; Moon JH; Hong SW; Shin JS; Hwang IY; Shin YJ; Kim JH; Gong EY; Kim SM; Lee EY; Lee S; Kim JE; Kim KP; Hong YS; Lee JS; Jin DH; Kim T; Lee WJ
Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
[TBL] [Abstract][Full Text] [Related]
6. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1.
Li Q; Xia X; Ji J; Ma J; Tao L; Mo L; Chen W
Oncotarget; 2017 May; 8(20):33621-33630. PubMed ID: 28422725
[TBL] [Abstract][Full Text] [Related]
7. TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma.
Xiao H; Tong R; Yang B; Lv Z; Du C; Peng C; Ding C; Cheng S; Zhou L; Xie H; Wu J; Zheng S
Cancer Lett; 2016 Oct; 381(2):370-9. PubMed ID: 27554639
[TBL] [Abstract][Full Text] [Related]
8. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
9. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Tusskorn O; Kukongviriyapan V
Life Sci; 2018 Aug; 207():172-183. PubMed ID: 29847773
[TBL] [Abstract][Full Text] [Related]
10. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
[TBL] [Abstract][Full Text] [Related]
11. Ascorbic acid uptaken by sodium-dependent vitamin C transporter 2 induces βhCG expression through Sp1 and TFAP2A transcription factors in human choriocarcinoma cells.
Chen L; Zhu H; Pan Y; Tang C; Watanabe M; Ruan H; Wang Y; Wang J; Yao HY; Iguchi T; Wu X
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1667-76. PubMed ID: 22745243
[TBL] [Abstract][Full Text] [Related]
12. Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Kukongviriyapan V
Life Sci; 2019 Jan; 217():155-163. PubMed ID: 30528773
[TBL] [Abstract][Full Text] [Related]
13. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
[TBL] [Abstract][Full Text] [Related]
14. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Jung DE; Park SB; Kim K; Kim C; Song SY
Sci Rep; 2017 Sep; 7(1):10921. PubMed ID: 28883618
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
17. Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage.
Yu W; Xiang Y; Luo G; Zhao X; Xiao B; Cheng Y; Feng C; Duan C; Xia X; Wong VKW; Dai R
Cancer Biother Radiopharm; 2018 Aug; 33(6):258-265. PubMed ID: 29957018
[TBL] [Abstract][Full Text] [Related]
18. Ascorbic acid transported by sodium-dependent vitamin C transporter 2 stimulates steroidogenesis in human choriocarcinoma cells.
Wu X; Iguchi T; Itoh N; Okamoto K; Takagi T; Tanaka K; Nakanishi T
Endocrinology; 2008 Jan; 149(1):73-83. PubMed ID: 17901237
[TBL] [Abstract][Full Text] [Related]
19. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
[TBL] [Abstract][Full Text] [Related]
20. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Yang SH; Lin HY; Chang VH; Chen CC; Liu YR; Wang J; Zhang K; Jiang X; Yen Y
Oncotarget; 2015 Sep; 6(27):23857-73. PubMed ID: 26160843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
